IDiyas

For the Inventor, By the Inventor

Camarillo, CA, United States of America

Wenyuan Qian

USPTO Granted Patents = 21 


 

Average Co-Inventor Count = 9.2

ph-index = 4

Forward Citations = 127(Granted Patents)


Location History:

  • Camarillo, CA (US) (2008 - 2015)
  • Newbury Park, CA (US) (2014 - 2017)
  • Thousand Oaks, CA (US) (2017 - 2021)

Company Filing History:

goldMedal21 out of 1,970 
 
Amgen Inc.
 patents
silverMedal1 out of 329 
 
Array Biopharma Inc.
 patents
where one patent can have more than one assignee

Years Active: 2008-2021

where 'Filed Patents' based on already Granted Patents

21 patents (USPTO):
1. 11021493 - 1,4-thiazine dioxide and 1,2,4-thiadiazine dioxide derivatives as beta-secretase inhibitors and methods of use (2021-06-01),
2. 10246429 - Vinyl fluoride cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use (2019-04-02),
3. 9663476 - Glycine transporter-1 inhibitors (2017-05-30),
4. 9611261 - Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use (2017-04-04),
5. 9550762 - Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use (2017-01-24),
6. 9493459 - Azetidine and piperidine compounds useful as PDE10 inhibitors (2016-11-15),
7. 9303028 - Azetidine and piperidine compounds useful as PDE10 inhibitors (2016-04-05),
8. 9296734 - Perfluorinated 5,6-dihydro-4H-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use (2016-03-29),
9. 9174992 - Heterobicyclic compounds (2015-11-03),
10. 9085576 - Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use (2015-07-21),
11. 8883782 - Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use (2014-11-11),
12. 8735383 - Glycine transporter-1 inhibitors (2014-05-27),
13. 8691986 - Azetidine and piperidine compounds useful as PDE10 inhibitors (2014-04-08),
14. 8426447 - Spiro-tricyclic ring compounds as beta-secretase modulators and methods of use (2013-04-23),
15. 8258306 - Glycine transporter-1 inhibitors (2012-09-04),

Title: Wenyuan Qian: Innovations in Beta-Secretase Inhibitors

Introduction

Wenyuan Qian, based in Camarillo, California, is an accomplished inventor with a remarkable portfolio of 21 patents. His contributions are primarily focused on developing innovative compounds targeting the beta-secretase enzyme, which plays a significant role in various neurological disorders.

Latest Patents

Among his latest patents are the derivatives of 1,4-thiazine dioxide and 1,2,4-thiadiazine dioxide, which serve as beta-secretase inhibitors. These compounds are crucial in modulating beta-secretase enzyme activity (BACE), presenting a promising approach for treating conditions related to the formation and deposition of amyloid-beta plaques. These conditions include Alzheimer's Disease, cognitive deficits, schizophrenia, and other central nervous system disorders. Another key patent involves Vinyl fluoride cyclopropyl fused thiazin-2-amine compounds, which are designed with similar therapeutic targets and applications.

Career Highlights

Wenyuan Qian has made significant strides in the field of biochemistry and pharmacology, particularly during his tenure at notable companies such as Amgen Inc. and Array Biopharma Inc. His work has not only advanced scientific understanding but also contributed to the development of potential therapeutic agents that address critical health challenges.

Collaborations

Throughout his professional journey, Wenyuan Qian has collaborated with talented individuals such as Qingyian Liu and Albert Kudzovi Amegadzie. These collaborations have fostered innovation and driven advancements in the research and development of beta-secretase inhibitors.

Conclusion

Wenyuan Qian's dedication to innovation and his substantial contributions to the field of beta-secretase inhibitors underscore the importance of his work in addressing neurological disorders. His patents shed light on promising therapeutic avenues, marking him as a significant figure in the landscape of medical research and pharmaceutical development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…